Journey Strategic Wealth LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Journey Strategic Wealth LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 722 shares of the pharmaceutical company’s stock after selling 61 shares during the period. Journey Strategic Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $291,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Czech National Bank increased its stake in shares of Vertex Pharmaceuticals by 6.9% in the third quarter. Czech National Bank now owns 52,578 shares of the pharmaceutical company’s stock worth $24,453,000 after buying an additional 3,404 shares during the period. GAMMA Investing LLC increased its holdings in Vertex Pharmaceuticals by 30.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,910 shares of the pharmaceutical company’s stock valued at $1,818,000 after purchasing an additional 909 shares during the period. Miracle Mile Advisors LLC raised its position in Vertex Pharmaceuticals by 14.9% during the 3rd quarter. Miracle Mile Advisors LLC now owns 5,816 shares of the pharmaceutical company’s stock valued at $2,705,000 after purchasing an additional 756 shares during the last quarter. New England Research & Management Inc. lifted its holdings in Vertex Pharmaceuticals by 67.3% in the 3rd quarter. New England Research & Management Inc. now owns 4,575 shares of the pharmaceutical company’s stock worth $2,128,000 after buying an additional 1,840 shares during the period. Finally, Mather Group LLC. increased its stake in shares of Vertex Pharmaceuticals by 2.0% during the third quarter. Mather Group LLC. now owns 4,015 shares of the pharmaceutical company’s stock valued at $1,867,000 after buying an additional 80 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Up 1.9 %

Shares of NASDAQ:VRTX opened at $470.37 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The company has a market cap of $121.13 billion, a P/E ratio of -236.37, a PEG ratio of 2.39 and a beta of 0.40. The stock’s fifty day moving average price is $434.55 and its 200-day moving average price is $462.75. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.67 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on VRTX shares. Scotiabank lifted their price target on shares of Vertex Pharmaceuticals from $430.00 to $433.00 and gave the company a “sector perform” rating in a report on Friday. Wells Fargo & Company lowered shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price on the stock. in a research note on Thursday, January 30th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday. Royal Bank of Canada lifted their price objective on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, UBS Group lifted their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.